Breast cancer is one of the most common cancers in humans and will on average affect up to one in eight women in their lifetime in the United States and Europe 1 . The Women's Health Initiative and the Million Women Study have shown that hormone replacement therapy is associated with an increased risk of incident and fatal breast cancer 2, 3 . In particular, synthetic progesterone derivatives (progestins) such as medroxyprogesterone acetate (MPA), used in millions of women for hormone replacement therapy and contraceptives, markedly increase the risk of developing breast cancer. Here we show that the in vivo administration of MPA triggers massive induction of the key osteoclast differentiation factor RANKL (receptor activator of NF-kB ligand) in mammary-gland epithelial cells. Genetic inactivation of the RANKL receptor RANK in mammary-gland epithelial cells prevents MPA-induced epithelial proliferation, impairs expansion of the CD49f hi stem-cell-enriched population, and sensitizes these cells to DNA-damage-induced cell death. Deletion of RANK from the mammary epithelium results in a markedly decreased incidence and delayed onset of MPA-driven mammary cancer. These data show that the RANKL/RANK system controls the incidence and onset of progestin-driven breast cancer.
, and we and others have proposed that the RANKL/RANK system can regulate bone metastases of epithelial tumours 9, 10 . On the basis of the clinical importance of RANKL inhibition being approved for potentially millions of patients to prevent bone loss 11 , the genetically defined role of RANKL/RANK in mammary epithelial proliferation in pregnancy 8 and the regulation of the RANKL/RANK system by sex hormones 8, 12 , we speculated that RANKL/RANK might affect the development of primary, hormone-driven mammary cancer.
Progesterone and its synthetic derivatives (progestins) are used in combined hormone replacement therapy in postmenopausal women 13 . MPA is the most frequently and longest used progestin in hormonal contraceptives 14 and is commonly used for hormone replacement therapy 15 . Because we 8 and others 12 have previously shown that progesterone can induce RANKL in vivo, we tested whether MPA can also induce RANKL expression. Treatment with MPA resulted in a more than 2,000-fold induction of messenger RNA encoding RANKL in isolated mammary epithelial cells (Fig. 1a) . Expression of mRNA encoding RANK, osteoprogesterin 16 , PTHrP (parathyroid-hormonerelated protein) and TRAIL (TNF-related apoptosis-inducing ligand) 16 were not changed. Immunohistochemistry confirmed the induction of RANKL protein in the mammary gland (Fig. 1b) . Western blotting showed induction of the 19-kDa soluble form of RANKL (Supplementary Fig. 1a ), most probably resulting from alternative splicing ( Supplementary Fig. 1b-d ) as well as induction of matrix metalloproteinase 14 and ADAM17 (a disintegrin and metalloproteinase 17, also called TACE (tumour-necrosis-factor-a-converting enzyme) (Supplementary Fig. 1e ), two proteases known to shed RANKL 16 . In addition, MPA might induce mammary-gland prolactin receptor, which then triggers RANKL by means of Jak-2/STAT5 signalling 17 . Whereas MPA triggers the substantial production of RANKL protein in female control mice, we failed to detect RANKL induction in prolactin receptor mutants ( Supplementary Fig. 1f ). Thus, MPA, through progesterone receptors, triggers massive RANKL expression in the mammary gland.
To examine the potential role of RANKL/RANK in MPA-mediated tumorigenesis we generated K5-Cre rank flox/D mice and murinemammary-tumour virus (MMTV)-Cre rank flox/D mice to delete RANK from mammary epithelial cells 7 . Both mouse lines seemed healthy. As expected from our previous studies on whole-body RANKL and RANK mutants 4, 8 , K5-Cre rank flox/D mice showed normal development of mammary glands in puberty; however, these mice did not develop milk-secreting structures during pregnancy ( Supplementary Fig. 2a-c) . In MMTV-Cre rank flox/D mice, the formation of milk-secreting lobuloalveolar structures in pregnancy seemed normal ( Supplementary Fig.  3a-c . MPA-induced proliferation of mammary epithelial cells was significantly decreased in RANK Dmam females ( Fig. 1c and Supplementary Fig. 4a-c) . Accordingly, intraperitoneal RANKL injections into nulliparous females triggered the proliferation of mammarygland epithelial cells through RANK ( Supplementary Fig. 4d, e) . Endogenous progesterone can affect the numbers of Lin-CD24 1 CD49f hi stem cells during pregnancy 19 and the oestrous cycle 20 . In these studies the RANKL/RANK system was implicated; however, it is not known whether this is a direct effect. Treatment with MPA resulted in a twofold expansion of Lin-CD24 1
CD49f
hi cells. This expansion did not occur in MPA-treated RANK Dmam females ( Fig. 1d and Supplementary Fig. 4f ). These data provide genetic proof that the RANKL/RANK system controls the expansion of Lin-CD24 1
hi cells. In the Women's Health Initiative and the Million Women Study, the use of progestins has been linked epidemiologically to the onset and incidence of breast cancer 2, 3 . Because RANKL is induced by MPA in vivo, we speculated that RANKL/RANK might affect sex-hormonedriven mammary cancer. Progestin-driven mammary cancer can be modelled in female mice 18 , in which the implantation of slow-release MPA pellets in the presence of the DNA-damaging agent 7,12-dimethylbenz[a]anthracene (DMBA) triggers mammary cancer ( Fig.  2a and Supplementary Fig. 5a, b) . In control females, treatment with MPA and DMBA induced a rapid onset of palpable mammary tumours. In RANK Dmam females we observed a marked delay in the onset of mammary cancer induced by MPA and DMBA ( Fig. 2b and Supplementary Fig. 5c, d ) and markedly enhanced survival (Supplementary Fig. 5e ). Southern blotting of the tumours that developed in RANK Dmam females confirmed the efficient deletion of RANK (Supplementary Information and Supplementary Fig. 5c ). All tumours that developed in control and RANK Dmam females showed a histopathology typical of E-cadherin 1 ductal adenocarcinomas of the cytokeratin5 1 (CK5
1
) and CK14 1 basal cell subtype ( Fig. 2c and Supplementary Fig. 6a, b) . Ductal adenocarcinomas arising in RANK Dmam females frequently developed extensive areas of squamous metaplasia ( Fig. 2c and Supplementary Fig. 6a, b) . In line with these histopathological changes, gene-expression profiling of mammary carcinomas from control and RANK Dmam females showed distinctive differences in their molecular signatures as assessed by gene clustering (Supplementary Information and Supplementary Fig. 7a-c) .
One week after the last DMBA treatment, all RANK-expressing control females already showed multiple in situ carcinomas and even invasive mammary tumours. By contrast, at this time point we observed very few carcinomas in situ and never any invasive mammary carcinomas in RANK Dmam animals (Fig. 2d) . Three weeks after the last DMBA challenge, the incidence of carcinomas in situ was similar in control and RANK Dmam females, but invasive carcinomas were still infrequent in the RANK Dmam mice (Fig. 2e) . Proliferation was typically decreased in tumours from RANK Dmam females (Fig. 2d, e) . Deletion of RANK in multiple other tissues including the liver, heart, muscle and the haematopoietic compartment, but not in mammary epithelial cells, using Mx-Cre rank flox/flox mice did not delay the onset of mammary cancer induced by MPA and DMBA ( Supplementary Fig. 8a-c) ,
suggesting that the effects of RANK deletion are restricted to mammary epithelial cells. In MMTV-NeuT transgenic mice, mammarygland-specific deletion of RANK did not alter the incidence of mammary cancer ( Supplementary Fig. 8d , e) or the histopathology of adenocarcinomas ( Supplementary Fig. 9a-c) . In NeuT tumours we observed very low levels of RANKL ( Supplementary Fig. 9d, e) . However, we cannot exclude effects of the RANKL/RANK system on some aspects of NeuT-driven tumorigenesis, for example metastatic behaviour. Thus, genetic inactivation of RANK in mammary epithelial cells results in a markedly delayed onset and decreased incidence of progestin-driven mammary cancer.
Previously, we 8 and others 21 have shown that the RANKL/RANK system signals through IkB kinase-a (IKK-a)-NF-kB-cyclin D1 in mammary epithelial cells ( Supplementary Fig. 10a ). Stimulation with RANKL did indeed result in p65 NF-kB and IkB-a phosphorylation in mouse primary mammary epithelial cells (MECs) (Fig. 3a) . In addition, stimulation of MECs with RANKL triggered phosphorylation of p38 mitogen-activated protein kinase (MAPKs) and extracellular signalregulated kinase (ERK) (Supplementary Fig. 10b) . A three-day in vivo treatment with MPA resulted in the accumulation of phosphorylated IkB-a in the nucleus, indicative of an active NF-kB pathway 22 , and the induction of cyclin D1 protein expression in mammary epithelial cells, both of which were severely decreased in RANK Dmam females (Supplementary Fig. 11a, b) . Moreover, in MPA/DMBA-induced mammary adenocarcinomas from control and RANK Dmam females we found impaired activation of the NF-kB pathway (Fig. 3b) and downregulated mRNA expression of cyclin D1 (Fig. 3c) . In these primary tumours we also observed upregulation of p21 mRNA (Fig. 3c) , a gene that is transcriptionally suppressed by the Id2 pathway 23 . The Id2 pathway is a second genetically confirmed downstream pathway for RANKL/RANK in mammary epithelial cells 23 . To extend these findings to humans we assayed SKBR3 breast tumour cells. Stimulation with RANKL induced NF-kB, p38 MAPKs and ERK activation and proliferation in SKBR3 cells ( Supplementary Fig. 12a, b) . We next assessed the ability of these cells to grow in an anchorage-independent manner, which correlates well with tumorigenicity in vivo 24 . In a similar manner 
LETTER RESEARCH
to stimulation with epidermal growth factor receptor, we observed that RANKL induced the growth of SKBR3 cells in soft agar (Fig. 3d) ; that is, RANK signalling not only triggers proliferation but also acts as a transforming agent to induce anchorage-independent growth.
In osteoclasts, besides the NF-kB pathway, the calcineurin-NFATc1 signalling pathway is essential for RANKL/RANK-mediated osteoclastogenesis 16 . NFATc1 can also be regulated by the Id2 pathway during RANKL-mediated osteoclastogenesis 25 . We therefore generated MMTV-Cre nfatc1 flox/D (NFATc1 (Fig. 3e) . In tumours from IKK-a Dmam mice we found normal expression of IKK-b and IKK-c but decreased NF-kB activation as determined by increased IkB protein levels and decreased p65 NF-kB phosphorylation (Fig. 3b) and downregulated mRNA expression of the NF-kB target gene encoding cyclin D1 (Fig. 3c) . As expected, the Id2 pathway gene p21 was not affected in tumours from IKK-a Dmam mice (Fig. 3c) . We did not observe any significant differences in tumour onset between control and NFATc1
Dmam mice (Supplementary Fig. 12c, d ), suggesting that downstream signalling requirements are different in osteoclast progenitors and mammary-gland epithelial cells. Thus, deletion of IKK-a, but not NFATc1, in mammary-gland epithelial cells affects the onset of progestin-driven mammary cancer.
Although treatment with MPA induces very rapid and massive proliferation of mammary epithelial cells, MPA alone is not sufficient to trigger mammary cancer, which requires a carcinogen to induce DNA mutations 18 . To analyse the role of RANKL in the cellular response to DNA damage, we treated MECs and the RANKL-responsive human breast cancer cell line SKBR3 with the DNA-damaging agents doxorubicin or c-irradiation. Treatment with RANKL did not alter the induction of c-H2AX and p53 or the activation of Chk1, prototypic markers of a functional DNA-damage response ( Supplementary  Fig. 13a ). Moreover, RANKL did not alter the early cell-cycle arrest after DNA damage with c-irradiation ( Supplementary Fig. 13b, c) or ). Anchorage-independent macroscopic colonies formed after 18 days in culture with RANKL, which was prevented by the decoy receptor osteoprogesterin (OPG) (1 mg ml
21
). Controls were unstimulated SKBR3 cells. e, Onset of palpable mammary tumours in IKKa Dmam (n 5 10) and age-matched littermate control (n 5 11) females treated with MPA pellets and DMBA. Data are shown as percentages of tumour-free mice after the last DMBA challenge. Median tumour onset for controls was 10 days after the last DMBA treatment, and for IKK-a Dmam females it was 24 days.
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doxorubicin ( Supplementary Fig. 14a, b) . However, treatment with RANKL resulted in marked protection from cell death in response to c-irradiation ( Supplementary Fig. 13b , c) and doxorubicin (Supplementary Fig. 14a, b) . Mechanistically, c-irradiation-induced upregulation of the pro-apoptotic molecules Bim, Puma and Noxa did not occur in the presence of RANKL (Supplementary Fig. 14c ). We next assessed the effects of the MPA-RANKL/RANK axis on c-irradiationinduced apoptosis of mammary epithelial cells 26 . Treatment with MPA did indeed give protection from c-irradiation-induced apoptosis of mammary epithelial cells in vivo. Loss of RANK expression on mammary epithelial cells abrogated the protective effects of MPA on c-irradiation-induced cell death (Fig. 4a, b) . Moreover, the IKK-a pathway is involved in MPA-induced protection of the mammary epithelium after c-irradiation ( Supplementary Fig. 15a, b) . Thus, in addition to promoting cell-cycle progression, MPA can protect from cell death after DNA damage, by means of RANKL/RANK and IKK-a signalling.
Recently it has been shown in humans and mice that mammary tumours might arise from stem-cell populations 27 . We therefore tested whether a loss of RANK affects mammary cancer stem cells; that is, tumour-initiating cells (TICs). TICs can be functionally assayed by their ability to form non-adherent mammospheres 27, 28 . Freshly isolated cancer cells from control and RANK Dmam females were able to form primary mammospheres; however, after dispersion into single cells the ability to form secondary mammospheres was significantly impaired when TICs from RANK Dmam mice were used (Fig. 4c, d ). These data indicate that a loss of RANK expression markedly impairs the selfrenewal capacity of putative cancer stem cells.
On the basis of our results we propose the following molecular model to explain how progestins such as MPA drive mammary cancer: MPA triggers an enormous induction of RANKL in the mammary gland. RANKL, through RANK on mammary epithelial cells, drives these cells into the cell cycle and protects mouse and human mammarygland epithelial cells from apoptosis in response to DNA damage. Moreover, the RANKL/RANK system controls self-renewal of TICs (defined by mammosphere assays) and anchorage-independent growth in vitro. Thus, the progestin-induced RANKL/RANK system provides a growth and survival advantage to damaged mammary epithelium, a prerequisite to the initiation of mammary cancer 29 . These effects seem to be mediated, at least in part, by IKK-a-NF-kB signalling.
These data have some intriguing implications. For instance, progestins have been associated with an increased risk of having an abnormal mammogram 30 . Because mammograms detect microcalcifications and glandular density 30 , and RANKL/RANK are crucial in bone metabolism 4, 5 , one could speculate that the RANKL/RANK system contributes to the calcification of such lesions and/or glandular densities. Millions of women take progesterone derivatives in contraceptives and for hormone replacement therapy. Because our results show that the RANKL/RANK system is an important molecular link between progestins and epithelial carcinogenesis, RANKL inhibition should be considered as a novel approach to the prevention and/or treatment of breast cancer.
METHODS SUMMARY
Mice. Mice carrying the rank flox allele, and MMTV-Cre, MMTV-NeuT, Mx-Cre, K5-Cre, IKKa flox and NFATc1 flox mice have been described previously (see Methods). In all experiments, only littermate mice from the same breedings were used. Mice were bred and maintained in accordance with institutional guidelines. MPA and DMBA-induced mammary carcinogenesis. Treatment with MPA and DMBA was performed as described 18, 28 . Six-week-old female mice were anaesthetized with ketamine-xylazine and subcutaneously implanted with slow-release MPA pellets (50 mg, 90-day release). DMBA (200 ml; 5 mg ml
21
) was administered by oral gavage six times throughout the following eight weeks as outlined in Fig. 2a . Onset of mammary tumours was determined by palpation. We did not observe differences in tumour onset in Cre-negative control females and littermates expressing the MMTV-Cre transgene, indicating that Cre expression does not itself alter tumour incidence in the MPA and DMBA mammary tumour model. Fluorescence-activated cell sorting (FACS) analysis of primary mammary epithelial cells. Purified mammary epithelial cells were stained with the following antibodies: biotin-conjugated anti-CD31 (catalogue no. 553371; BD), which labels endothelial cells, and biotinylated CD45 1 and Ter119 1 (StemSep murine chimaera cocktail, catalogue no. 13058C; Stem Cell Technologies) both of which label haematopoietic cells. Haematopoietic and endothelial cells were excluded by FACS with streptavidin-conjugated allophycocyanin (catalogue no. 554067; BD). Staining with anti-CD49f (catalogue no. 551129; BD) and CD24 (catalogue no. 553261; BD) was used to identify the mammary-stem-cell-enriched population 37, 38 . Mammosphere assays. Similar-sized tumours (1 cm 3 volume) were digested in complete EpiCult medium with 2.5 3 collagenase/hyaluronidase. Cells (2 3 10 5 ) were then cultured in serum-free EpiCult medium supplemented with B27 (Invitrogen), 20 ng ml 21 epidermal growth factor (Protech) and 20 ng ml 21 basic fibroblast growth factor (Sigma), using ultra-low-attachment plates. Primary mammospheres were collected on day 7, digested into single-cell suspensions with trypsin, and assayed for their ability to form secondary mammospheres 28, 39 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. In all experiments described in this paper, only littermate mice from the same breedings were used. All mice were bred and maintained in accordance with institutional guidelines. Mammary carcinogenesis induced with MPA and DMBA. Treatment with MPA and DMBA was performed as described 18, 28 . In brief, six-week-old female mice were anaesthetized with ketamine-xylazine and surgically implanted with slow-release MPA pellets (50 mg, 90-day release; Innovative Research of America) subcutaneously on the right flank. DMBA (200 ml; 5 mg ml 21 diluted in cottonseed oil) was administered by oral gavage six times throughout the following eight weeks as outlined in Fig. 2a . Onset of mammary tumours was determined by palpation. We did not observe differences in tumour onset in Cre-negative control females and littermates expressing the MMTV-Cre transgene, indicating that Cre expression does not itself alter tumour incidence in the MPA and DMBA mammary tumour model. Mammary tissue transplants. For transplantation studies, mammary epithelial tissue was isolated from nulliparous three-week-old donors and implanted into cleared mammary fat pads (devoid of endogenous epithelium) of three-week-old host nu/nu mice as described 40 . Cleared fat-pad transplantation is a standard technique in mammary-gland biology to assess the cell-autonomous effect of genetic ablation studies 40 . The mammary anlage is laid down close to the nipple and will only start to grow through the mammary fat pad during puberty, giving rise to the mammary epithelial tree. This epithelial anlage can be removed ('cleared') by surgery in three-week-old mice, leaving the bulk of the fat pad free of epithelium. Transplantation of primary mammary epithelial cells from a donor mouse results in the outgrowth of these cells into a functional mammary epithelial tree with luminal and myoepithelial cells that can generate milk-secreting alveoli on pregnancy. In our experiments, three weeks after surgery, host females were mated and, in all cases, mammary tissue was isolated for analysis on day 1 of lactation. Histology, whole-mount staining and immunohistochemistry. For histological analysis, 5-mm sections were cut and stained with haematoxylin and eosin. Wholemount staining of mammary glands was performed as described 8 . For immunoperoxidase staining, paraffin-embedded sections were dehydrated and antigenic epitopes were exposed by using a 10 mM citrate buffer and microwaving. Sections were incubated with antibodies against cytokeratin 5, cytokeratin 14, E-cadherin, anti-Ki67 (Novocastra) and anti-active caspase-3 (Cell Signaling) and revealed with peroxidaseconjugated secondary antibodies. Histomorphometric indices (proliferation and apoptosis) were calculated as the number of positive epithelial cells divided by the total number of epithelial cells, with no fewer than 1,000 nuclei for Ki67 stainings and no fewer than 5,000 cells for active caspase-3 staining counted per section. Western blotting. The human epithelial breast tumour cell line SKBR3 and primary non-transformed mouse mammary epithelial cells were left untreated or stimulated with recombinant murine RANKL 41 . Adenocarcinomas were isolated from control and mutant mice and total protein lysates were prepared. Western blotting was performed with standard protocols. In brief, blots were blocked for 1 h with 5% BSA in 10 mM Tris-HCl pH 7.5, 150 mM NaCl containing 0.1% Tween 20 (TBST) and incubated overnight with primary antibody at 4 uC (diluted in TBST in accordance with the manufacturer's protocol). Primary antibodies reactive to mouse). Cell-cycle arrest and numbers of dead cells were determined by staining with propidium iodide. To determine in vivo mammary-gland epithelial cell death, control and RANK Dmam littermate females were c-irradiated with a total dose of 5 Gy. Six hours later, mammary glands were isolated and immunostained for active caspase-3 (Cell Signaling), indicative of apoptosis. FACS analysis of primary mammary epithelial cells. For FACS analysis of mammary epithelial subpopulations, the following protocol for tissue dissociation was used to generate single-cell suspensions: lymph nodes were removed from both inguinal mammary fat pads; fat pads were then digested for 2.5 h in 2 ml of complete EpiCult medium (EpiCult-B basal medium; catalogue no. 05610; StemCell Technologies) supplemented with EpiCult-B proliferation supplements, 10 ng ml heparin (catalogue no. 07980; StemCell Technologies), 2.5 ml of FBS (5%) and antibiotics) with 2.5 3 collagenase/hyaluronidase (for example, 500 ml of 103 collagenase plus 1.5 ml of Epicult per mouse) (catalogue no. 07912; StemCell Technologies) in 50-ml Falcon tubes at 37 uC. After vigorous vortex-mixing, pellets were washed with 10 ml of HF medium (Hanks Balanced Salt Solution Modified (catalogue no. 07913; StemCell Technologies) plus 2% FBS). Pellets were then resuspended in 2 ml of prewarmed trypsin-EDTA. After a further wash with 10 ml of HF medium, pellets were resuspended in 2 ml of prewarmed (37 uC) dispase (catalogue no. 07913; StemCell Technologies) supplemented with 200 ml of 1 mg ml 21 DNase I (catalogue no. 07900; StemCell Technologies). After a final wash in HF, cells were counted and prepared for FACS staining. Cells (10 6 ) were incubated with the following antibodies: biotin-conjugated anti-CD31 (catalogue no. 553371; BD), which labels endothelial cells, and biotinylated CD45 1 and Ter119 1 (StemSep murine chimaera cocktail; catalogue no. 13058C; Stem Cell Technologies; 3.5 ml per 100 ml), which labels haematopoietic cells, for 10 min at room temperature. Haematopoietic and endothelial cells were excluded by FACS with streptavidin-conjugated allophycocyanin (catalogue no. 554067; BD). Staining with anti-CD49f (catalogue no. 551129; BD) and CD24 (catalogue no. 553261; BD) was used to identify the mammary-stem-cell population as described previously 37, 38 . Cancer stem-cell assays. Self-renewal of mammary cancer stem cells (TICs) was assayed with a mammosphere assay as described previously 28, 39 . In brief, similar-sized tumours (1 cm 3 volume) were minced and digested in complete EpiCult medium with 2.5 3 collagenase/hyaluronidase (catalogue no. 07912; Stem Cell Technologies). Cells (2 3 10 5 ) were then cultured in serum-free EpiCult medium supplemented with B27 (Invitrogen), 20 ng ml 21 epidermal growth factor (Protech) and 20 ng ml 21 basic fibroblast growth factor (Sigma), using six-well ultra-low-attachment plates (Corning Costar). The primary mammospheres, which formed over 7 days, were collected by gentle centrifugation (60g), digested into single-cell suspensions with trypsin (0.05%, 10 min), and assayed for their ability to form secondary mammospheres as above.
Anchorage-independent growth. The ability of cells to grow in soft agar was assayed as described previously 24 . In brief, DNA-grade agarose (1% in DMEM) was used as the bottom layer (2 ml in six-well plates) and 2 3 10 4 SKBR3 cells were seeded in 1.5 ml of agarose (0.3% in DMEM). Cells were overlaid with 1.5 ml of DMEM supplemented with 10% FCS and cultured for 24 days. Statistics. All values in the paper are given as means 6 s.e.m. Comparisons between groups were made with Student's t-test. For the Kaplan-Meier analysis of tumour onset, a log-rank test was performed. P , 0.05 was accepted as statistically significant. In addition to the log-rank test a post-hoc power analysis was performed (PS Power and Sample Size Calculations, http://biostat.mc.vanderbilt.edu/PowerSampleSize) to LETTER RESEARCH
